Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 21;13(12):1578.
doi: 10.3390/antiox13121578.

Cisplatin-Induced Hearing Loss, Oxidative Stress, and Antioxidants as a Therapeutic Strategy-A State-of-the-Art Review

Olaf Rose  1   2 , Tim Croonenberg  1 , Stephanie Clemens  1   2 , Tobias Hinteregger  1 , Stefanie Eppacher  1 , Petra Huber-Cantonati  1 , Marta Garcia-Miralles  1 , Raffaella Liuni  3 , Silvia Dossena  3   4
Affiliations
Review

Cisplatin-Induced Hearing Loss, Oxidative Stress, and Antioxidants as a Therapeutic Strategy-A State-of-the-Art Review

Olaf Rose et al. Antioxidants (Basel). .

Abstract

Cisplatin is an established component of treatment protocols for various solid malignancies but carries a significant potential for serious adverse effects. Ototoxicity from cisplatin treatment is an important dose-limiting toxicity that manifests as bilateral, progressive, irreversible, dose-dependent sensorineural hearing loss, ear pain, tinnitus, and vestibular dysfunction. Despite the recent approval of sodium thiosulphate for the prevention of cisplatin-induced hearing loss (CIHL) in pediatric patients, structured prevention programs are not routinely implemented in most hospitals, and reducing platinum-induced ototoxicity in adults remains an important clinical problem without established treatment options. Cochlear oxidative stress plays a fundamental role in CIHL. Here, we review the molecular mechanisms leading to oxidative stress in CIHL and the clinical and preclinical studies testing antioxidants in CIHL to guide future clinical trials in assessing the efficacy and safety of candidate antioxidant compounds in this clinical setting.

Keywords: antioxidants; cisplatin; cisplatin-induced hearing loss (CIHL); hearing loss; ototoxicity; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Schematic representation of a cross-section of the cochlea.
See this image and copyright information in PMC

References

    1. Zhang C., Xu C., Gao X., Yao Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 2022;12:2115–2132. doi: 10.7150/thno.69424. - DOI - PMC - PubMed
    1. Johnstone T.C., Suntharalingam K., Lippard S.J. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem. Rev. 2016;116:3436–3486. doi: 10.1021/acs.chemrev.5b00597. - DOI - PMC - PubMed
    1. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., Topham C., Zaninelli M., Clingan P., Bridgewater J., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 2004;350:2343–2351. doi: 10.1056/NEJMoa032709. - DOI - PubMed
    1. Andre T., Louvet C., Raymond E., Tournigand C., de Gramont A. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann. Oncol. 1998;9:1251–1253. doi: 10.1023/A:1008475122124. - DOI - PubMed
    1. Beijer Y.J., Koopman M., Terhaard C.H., Braunius W.W., van Es R.J., de Graeff A. Outcome and toxicity of radiotherapy combined with chemotherapy or cetuximab for head and neck cancer: Our experience in one hundred and twenty-five patients. Clin. Otolaryngol. 2013;38:69–74. doi: 10.1111/coa.12002. - DOI - PubMed

LinkOut - more resources